LINC02213

Across TCGA pan-cancer cohorts, LINC02213 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated LINC02213 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher LINC02213 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LINC02213 expression acts as an unfavorable survival marker, although some lineages such as BRCA and LAML show a favorable association.

CHOL, BRCA, and BLCA are the cancer types where LINC02213 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	All	0.019	0.800	<.001	72	view →
BRCA	OS	Tertile	All	0.717	0.567	.010	72	view →
BLCA	DFS	Tertile	All	0.419	0.621	.020	39	view →
MESO	DFS	Tertile	All	0.159	0.402	.010	36	view →
LUSC	OS	Tertile	IV	0.001	0.673	.014	36	view →
SKCM	OS	Tertile	All	0.585	0.791	.013	33	view →
ACC	DFS	Tertile	All	0.123	0.601	.005	27	view →
KIRC	OS	Quartile	All	0.499	0.675	.001	21	view →
KIRP	DFS	Tertile	II,III,IV	0.176	0.604	.012	18	view →
LAML	DFS	Median	All	0.561	0.246	.004	18	view →
THCA	DFS	Tertile	III,IV	0.145	0.765	.003	9	view →
TGCT	DFS	Tertile	All	0.150	0.684	.006	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

LINC02213–CHOL (OS)

Open the CHOL breakdown →